Summit Therapeutics plc Summit Therapeutics Plc : Director/Pdmr Shareholding
17 July 2018 - 4:00PM
UK Regulatory
TIDMSUMM
Summit Therapeutics plc
("Summit" or the "Company")
Director / PDMR Share Dealing
Oxford, UK, Cambridge, MA, US, 17 July 2018 - Summit Therapeutics plc
(AIM: SUMM, NASDAQ: SMMT), announces that it was notified on 16 July
2018 that Dr Frank Armstrong, Summit's Non-Executive Chairman, purchased
25,000 ordinary shares of 1p each in the Company at 39.5 pence per
share.
Following this purchase, his shareholding in the Company has increased
to 39,442 ordinary shares, representing approximately 0.05% of the
Company's issued share capital.
The notification set out below is provided in accordance with the
requirements of the EU Market Abuse Regulation.
Notification of a Transaction pursuant to Article 19(1) of Regulation
(EU) No. 596/2014
Details of the person discharging managerial responsibilities/person
1 closely associated
a) Name Frank Armstrong
2 Reason for the notification
a) Position / status Non-Executive Chairman
b) Initial notification / Amendment Initial notification
Details of the issuer, emission allowance market participant,
3 auction platform, auctioneer or auction monitor
a) Name Summit Therapeutics plc
b) LEI 213800NRW8AOMYMTBD89
Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
4 where transactions have been conducted
Description of the financial
a) instrument, type of instrument Ordinary shares of 1 pence each
Identification code GB00BN40HZ01
b) Nature of the transactions Purchase of ordinary shares
c) Price(s) and volume(s) Price(s) Volume(s)
39.5 pence 25,000
d) Aggregated information
- Aggregated volume
- Price
e) Date of the transaction 16 July 2018
f) Place of the transaction London Stock Exchange
About Summit Therapeutics
Summit Therapeutics is a leader in antibiotic innovation. Our new
mechanism antibiotics are designed to become the new standards of care
for the benefit of patients, and create value for payors and healthcare
providers. We are currently developing new mechanism antibiotics for C.
difficile infection and gonorrhoea and are using our proprietary Discuva
Platform to expand our pipeline. For more information, visit
www.summitplc.com and follow us on Twitter @summitplc.
For more information, please contact:
Summit
Glyn Edwards / Richard Pye (UK office) Tel: 44 (0)1235 443 951
Erik Ostrowski / Michelle Avery (US office) +1 617 225 4455
Cairn Financial Advisers LLP (Nominated Adviser) Tel: +44 (0)20 7213 0880
Liam Murray / Tony Rawlinson
-END-
This announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the information
contained therein.
Source: Summit Therapeutics plc via Globenewswire
http://www.summitplc.com/
(END) Dow Jones Newswires
July 17, 2018 02:00 ET (06:00 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Summit Therapeutics (LSE:SUMM)
Historical Stock Chart
From Apr 2024 to May 2024
Summit Therapeutics (LSE:SUMM)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Summit Therapeutics Plc (London Stock Exchange): 0 recent articles
More Summit Ther News Articles